Fortress Biotech Financial Overview and Stock Details

Fortress Biotech is a biopharmaceutical company that has been making waves in the industry. It was founded in 2006 by Lindsay A. Rosenwald, a successful entrepreneur with a background in biotechnology.

Fortress Biotech has a diverse portfolio of companies, including its flagship company, Fortress Biotech Inc. This company is a biopharmaceutical company focused on developing and commercializing treatments for various diseases.

As of 2022, Fortress Biotech Inc. has a market capitalization of approximately $120 million. This is a significant milestone for the company, indicating its growth and potential for future success.

Fortress Biotech Inc. is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol FBIO.

Broaden your view: Fortress Transportation and Infrastructure Investor Relations

Fortress Biotech's financial performance is a mixed bag. As of 10/24/2025, the company's trailing total returns, which may include dividends or other distributions, are comparable to its benchmark, the S&P 500 (^GSPC).

The company's balance sheet is also notable, with a total cash of $74.39M and a total debt/equity ratio of 185.16% as of the most recent quarter. This suggests that the company has a significant amount of debt compared to its equity.

The company's profitability is, however, a concern, with a profit margin of -24.84% and a return on assets (ttm) of -40.94%. This indicates that the company is struggling to generate profits from its assets and operations.

Here is a summary of the company's financial performance:

As of 10/8/2025, the trailing total returns for FBIOP may include dividends or other distributions.

The benchmark for evaluating FBIOP's performance is the S&P 500 (^GSPC), a widely recognized and followed stock market index.

FBIOP's performance is likely to be compared to the S&P 500's returns over the same period.

Here's a quick snapshot of some key metrics for FBIOP:

These metrics suggest that FBIOP has experienced significant losses in terms of profitability and income.

Looking at the Profitability and Income Statement, we can see some concerning trends. Profit Margin is a staggering -24.84%, indicating that the company is losing money on every sale. This is a red flag for investors.

The Return on Assets (ROA) is also alarming, at -40.94%. This means that the company is generating losses that are more than 40% of its total assets. It's a sign that the company's assets are not generating the expected returns.

Return on Equity (ROE) is similarly dismal, at -784.32%. This means that for every dollar invested in the company, it's losing nearly $8 in value. This is a clear indication of poor management and a lack of profitability.

Revenue is still a respectable $59.3M, but it's not enough to offset the significant losses. Net Income Avi to Common is a negative $24.05M, which is a clear indication of the company's financial struggles.

Here are the key metrics from the Profitability and Income Statement:

Fortress Biotech's financial situation is quite concerning. Total Cash is a staggering $74.39 million, indicating a sizeable amount of liquid assets.

However, when we look at the company's debt-to-equity ratio, it's a different story. With a Total Debt/Equity ratio of 185.16%, Fortress Biotech is heavily indebted, which can be a major red flag for investors.

Here's an interesting read: Fortress Investment Group

Let's break down the company's cash flow situation. Levered Free Cash Flow (ttm) is a negative $61.88 million, suggesting that Fortress Biotech is not generating sufficient cash to cover its expenses.

Here's a summary of the company's financial situation:

The company's profitability is also a concern, with a Profit Margin of -24.84% and a Return on Assets (ttm) of -40.94%. This suggests that Fortress Biotech is struggling to generate profits and is not using its assets efficiently.

Fortress Biotech and its subsidiary Urica Therapeutics have been making waves in the biotech industry with some significant announcements.

Fortress Biotech's subsidiary Urica Therapeutics sold dotinurad to Crystalys Therapeutics in 2024.

Crystalys Therapeutics secured a $205 million Series A financing to advance global Phase 3 clinical trials for dotinurad, a next-generation URAT1 inhibitor for gout treatment.

Urica Therapeutics maintains an equity stake in Crystalys and will receive a 3% royalty on future dotinurad net sales.

The drug has already received approval in Japan, China, Philippines, and Thailand.

Fortress Biotech also highlighted its recent achievement of selling subsidiary Checkpoint Therapeutics to Sun Pharma.

The deal earned Fortress Biotech $28 million upfront, plus potential CVR payments and royalties on UNLOXCYT sales.

You might like: Fortress Re

Fortress Biotech is participating in the H.C. Wainwright 27th Annual Global Investment Conference.

The conference will take place from September 8-11, 2025, and the company will be available for virtual one-on-one meetings during this time.

CEO Lindsay A. Rosenwald will deliver a corporate overview presentation, which will be available for on-demand viewing starting September 5, 2025, at 7:00 a.m. ET.

Here's the stock details section of the article:

The ticker symbol for the stock is FBIOP, which is listed on the NASDAQ exchange. This is a key piece of information for any investor looking to track the stock's performance.

The stock type is preferred stock, which means it has a higher claim on assets and earnings than common stock. This can be an attractive option for investors looking for a higher return.

Here are the key details about the stock:

The fiscal year for the company runs from January to December, which is a standard calendar year for most publicly traded companies. This means that the company's financial reports will be released on a regular schedule, making it easier to track its performance.

The H.C. Wainwright 27th Annual Global Investment Conference is an event you won't want to miss. Fortress Biotech, a biopharmaceutical company, will be participating in the conference.

CEO Lindsay A. Rosenwald will deliver a corporate overview presentation, which will be available for on-demand viewing by conference attendees starting September 5, 2025, at 7:00 a.m. ET.

The conference will take place from September 8-11, 2025, and attendees can schedule virtual one-on-one meetings with the company.

Fortress Biotech's financial situation is a mixed bag. The company has a significant amount of total cash, standing at $74.39 million as of the most recent quarter.

This cash is not being used effectively, however, as the company's levered free cash flow is -$61.88 million over the trailing 12 months. This suggests that Fortress Biotech is struggling to generate positive cash flow from its operations.

The company's debt-to-equity ratio is a concerning 185.16%, indicating a high level of debt relative to its equity. This may put pressure on the company's financial situation and make it harder to access additional funding.

Here are the key financial metrics:

Fortress Biotech, the parent company of Urica Therapeutics, has had a significant year with notable financial highlights. The company recently announced a $205 million Series A financing for Crystalys Therapeutics to advance global Phase 3 clinical trials for dotinurad, a next-generation URAT1 inhibitor for gout treatment.

Urica Therapeutics, a subsidiary of Fortress Biotech, sold dotinurad to Crystalys in 2024 and will receive a 3% royalty on future dotinurad net sales. This deal is a testament to the potential of Urica's research and development.

The company also highlighted its recent achievement of selling subsidiary Checkpoint Therapeutics to Sun Pharma, receiving $28 million upfront plus potential CVR payments and royalties on UNLOXCYT sales. This deal demonstrates Fortress Biotech's ability to drive growth through strategic partnerships.

As of 10/24/2025, Fortress Biotech's trailing total returns include dividends or other distributions, and the company's performance is benchmarked against the S&P 500.

Let's take a closer look at the valuation measures of this company. The market capitalization is a significant $83.31 million.

This is a substantial amount of money, and it's essential to understand how it affects the company's overall value. The enterprise value is slightly lower, at $78.15 million.

One key valuation metric is the price-to-sales ratio, which is 1.25. This means that the company's stock price is 1.25 times its revenue.

The price-to-book ratio is also noteworthy, standing at 1.90. This indicates that the company's stock price is 1.90 times its book value.

Here's a summary of the valuation measures:

Let's take a closer look at the financial highlights of this company. The total cash on hand is a respectable $74.39 million.

This cash reserve is a crucial factor in a company's ability to weather financial storms and invest in new opportunities. However, the total debt to equity ratio is a whopping 185.16%, which suggests that the company may be taking on too much debt.

The levered free cash flow is a negative $61.88 million, which means the company is actually losing money after accounting for debt payments. This is a concerning trend that should be closely monitored by investors.

Here are the key financial highlights in a quick glance: